The DOI matches its Crossref record.
A New Primaquine Analogue, Tafenoquine (WR 238605), for Prophylaxis against Plasmodium falciparum Malaria
Abstract
We tested tafenoquine (WR 238605), a new long-acting 8-aminoquinoline, for its ability to prevent malaria in an area that is holoendemic for Plasmodium falciparum. In a double-blinded, placebo-controlled, randomized clinical trial in western Kenya, adult volunteers received a treatment course of 250 mg halofantrine per day for 3 days, to effect clearance of preexisting parasites. The volunteers were then assigned to 1 of 4 drug regimens: placebo throughout; 3 days of 400 mg (base) of tafenoquine per day, followed by placebo weekly; 3 days of 200 mg of tafenoquine per day, followed by 200 mg per week; and 3 days of 400 mg of tafenoquine per day, followed by 400 mg per week. Prophylaxis was continued for up to 13 weeks. Of the evaluable subjects (223 of 249 randomized subjects), volunteers who received 400 mg tafenoquine for only 3 days had a protective efficacy of 68% (95% confidence interval [CI], 53%-79%), as compared with placebo recipients; those who received 200 mg per day for 3 days followed by 200 mg per week had a protective efficacy of 86% (95% CI, 73%-93%); and those who received 400 mg for 3 days followed by 400 mg per week had a protective efficacy of 89% (95% CI, 77%-95%). A similar number of volunteers in the 4 treatment groups reported adverse events. Prophylactic regimens of 200 mg or 400 mg of tafenoquine, taken weekly for < or =13 weeks, are highly efficacious in preventing falciparum malaria and are well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Oxidative stress in malaria parasite-infected erythrocytes: host–parasite interactions
Becker, K., Tilley, L., Vennerstrom, J. L., Roberts, D., Rogerson, S., & Ginsburg, H. (2004) · International Journal for Parasitology · doi:10.1016/j.ijpara.2003.09.011 · Cited by 652
Fluorine‐Containing Drugs Approved by the FDA in 2018
Mei, H., Han, J., Fustero, S., Medio‐Simon, M., Sedgwick, D. M., Santi, C., Ruzziconi, R., & Soloshonok, V. A. (2019) · Chemistry – A European Journal · doi:10.1002/chem.201901840 · Cited by 454
Wiesner, J., Ortmann, R., Jomaa, H., & Schlitzer, M. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200200569 · Cited by 428
Operational strategies to achieve and maintain malaria elimination
Moonen, B., Cohen, J. M., Snow, R. W., Slutsker, L., Drakeley, C., Smith, D. L., Abeyasinghe, R. R., Rodriguez, M. H., Maharaj, R., Tanner, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61269-x · Cited by 381
Primaquine revisited six decades after its discovery
Vale, N., Moreira, R., & Gomes, P. (2009) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2008.08.011 · Cited by 367
Metadata
- Authors
- Shanks, G. D., Oloo, A. J., Aleman, G. M., Ohrt, C., Klotz, F. W., Braitman, D., Horton, J., & Brueckner, R.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-12-15
- Volume
- 33
- Issue
- 12
- Pages
- 1968-1974
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2134780685
- Cited by
- 168
- References
- 0
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A New Primaquine Analogue, Tafenoquine (WR 238605), for Prophylaxis against Plasmodium falciparum Malaria. https://app.cochat.ai/papers/10.1086/324081
- The paper
- Shanks, G. D., Oloo, A. J., Aleman, G. M., Ohrt, C., Klotz, F. W., Braitman, D., Horton, J., & Brueckner, R. (2001). A New Primaquine Analogue, Tafenoquine (WR 238605), for Prophylaxis against Plasmodium falciparum Malaria. Clinical Infectious Diseases. https://doi.org/10.1086/324081
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.